START FREE TRIAL

Baker Hughes Eyes Chart Industries: A $13.6B Bet On LNG & Digital Power

AI Summary

🔒 UNLOCK AI SUMMARY WITH FREE TRIAL

START FREE TRIAL

Baker Hughes Eyes Chart Industries: A $13.6B Bet On LNG & Digital Power

Baker Hughes is reportedly nearing a $13.6 billion all-cash acquisition of Chart Industries, potentially derailing Chart’s previously announced all-stock merger with Flowserve. The proposed deal, which values Chart at $210 per share—a 22% premium to its latest closing price—marks a significant strategic pivot by Baker Hughes toward enhancing its footprint in liquefied natural gas (LNG), nuclear energy, and digital infrastructure, particularly data centers. By superseding the $19 billion Flowserve-Chart merger agreement from June, Baker Hughes aims to consolidate its position in high-growth, energy-adjacent sectors through vertical integration and technology enhancement. This potential acquisition comes on the heels of Baker Hughes’ strong Q2 2025 performance, where the company posted $1.21 billion in adjusted EBITDA and highlighted robust momentum in Industrial & Energy Technology (IET), particularly from power equipment orders tied to data centers. Here’s a closer look at the four key drivers behind this potential acquisition and how it may unlock synergies across Baker Hughes’ diverse portfolio.

Expanding LNG Infrastructure & Equipment Synergies

A core rationale behind Baker Hughes’ interest in acquiring Chart Industries is the complementary fit between Chart’s cryogenic equipment and process technologies and Baker Hughes’ existing gas infrastructure offerings. Chart brings deep expertise in storage tanks, heat exchangers, and liquefaction systems, which could significantly strengthen Baker Hughes’ ability to provide turnkey solutions for…

Continue Reading With Our 7-Day Free Trial

ONLY $10 per month after the trial. Cancel anytime. No sponsors. No conflicts. 100% independent stock research.

Recent Articles

Nike’s China Slump Is Starting to Look Like Something More!

Nike (NYSE:NKE) has spent years selling the idea that...

This “Broken” Biotech Just Forced Wall Street To Blink

Apellis Pharmaceuticals (NASDAQ:APLS) did not suddenly discover a miracle...

Tesla Is Quietly Killing Its Own Cars—& What Comes Next Could Be MUCH BIGGER

For years, most investors have approached Tesla as an...

This Medical Device Stock Just Got CRUSHED On One Hidden Number; Did Wall Street Misread It?

Boston Scientific (NYSE:BSX) spent the weekend putting forward what...

This Widely Held “Defensive” Stock Is Now Tied To A Large Scale Merger

For years, McCormick (NYSE:MKC) has been framed as one...

Related Articles

Nike’s China Slump Is Starting to Look Like Something More!

Nike (NYSE:NKE) has spent years selling the idea that...

This “Broken” Biotech Just Forced Wall Street To Blink

Apellis Pharmaceuticals (NASDAQ:APLS) did not suddenly discover a miracle...

Tesla Is Quietly Killing Its Own Cars—& What Comes Next Could Be MUCH BIGGER

For years, most investors have approached Tesla as an...

This Medical Device Stock Just Got CRUSHED On One Hidden Number; Did Wall Street Misread It?

Boston Scientific (NYSE:BSX) spent the weekend putting forward what...

This Widely Held “Defensive” Stock Is Now Tied To A Large Scale Merger

For years, McCormick (NYSE:MKC) has been framed as one...

A First-In-Class Biotech Is Still Trading Below Its Strategic Value Today

A mid-cap biotech with the first approved therapy in...
spot_img

Related Articles

Popular Categories

spot_imgspot_img